Tata Consultancy Services Partners with Dassault Systems to Drive Digital Transformation in Cardiovascular Science through Bio-Physical Simulation
NEW YORK | MUMBAI, September 11, 2023: Tata Consultancy Services (TCS) (BSE: 532540, NSE: TCS) has partnered with Dassault Systems through its Living Heart Project that unites an ecosystem of cardiovascular researchers, educators, medical device developers, regulatory agencies including US FDA, and practicing cardiologists, to develop and validate realistic digital simulations of the human heart.
The project will create groundbreaking medical solutions, including the use of heart simulation as a source of digital evidence for new cardiovascular device approvals. This includes an in-silico clinical trial that could complement the evidence drawn from clinical subjects while reducing the need for animal testing and human enrollment for clinical trials.
As an industry partner, TCS will use its domain and technology expertise, and its research on the Digital BioTwin of the heart to contribute to model refinement, simulation, and technological implementation in developing and validating highly accurate, personalized digital human heart models.
The TCS Digital BioTwin is a biophysics-based high-fidelity computational model developed by TCS’ researchers, to enable investigation of the function of a particular human organ remotely and non-invasively. It helps in understanding the individual contributions of several factors and analyzes their interactions at a spatial scale. TCS has been conducting extensive research in building digital bio-twins of organs such as skin, nose, and colon. To complement this research, TCS will also collaborate with Dassault Systems and others towards the goal of a Virtual Human Twin, with a focus on select organs identified as critical for the advancement of the field.
“We are delighted to welcome Tata Consultancy Services to our Living Heart Project,” said Steve Levine, Sr. Director, Virtual Human Modeling, Dassault Systèmes and founder of The Living Heart Project, “Their deep expertise in research and technology development will bring invaluable insights to our mission and to others in the field. This collaboration demonstrates our shared commitment to leveraging the virtual world for the advancement of medical science and patient care. By joining forces, we believe we can accelerate the pace of innovation and make significant strides towards our goal of creating and delivering personalized in-silico medical solutions.”
“TCS is excited to be a part of the Living Heart initiative, and to collaborate in creating a pathbreaking digital simulation of the human heart that can enrich our understanding of the cardiac function and provide insights for novel cardiac treatments and new product development for the med-tech and pharma sectors. We believe that our extensive expertise in building digital bio-twins for other organs and body parts positions us well to contribute significantly to this collaborative initiative,” said Vikram Karakoti, Global Head, Life Sciences Business, TCS.
TCS collaborates with leading life sciences companies across the world to enable their digital transformation journeys. The company provides a full set of services spanning advisory, IT and cognitive business operations and solutions across the life sciences value chain, including data and analytics, predictive and prescriptive analytics, genomics research, blockchain enabled clinical supply chain, AI enabled case processing, discovery collaboration, cognitive research, and digital labs. The solutions use a combination of artificial intelligence, cognitive computing capabilities, robotic process automation, Internet of Things, and cloud to fully digitize the life sciences value chain.